Figures & data
Figure 1 Antibody Staining for presence of NMDA Receptors.
Notes: (A) Immunohistochemical staining of ovarian cancers from three patients. I, Positive staining of tumors with NMDAR1 antibodies; II, negative staining of normal adjacent tissue; III, negative staining with antibodies blocked by 20 µg/mL peptide antigen. (B) Sodium dodecyl sulfate polyacrylamide-gel electrophoresis using 12.5% gels and Western blot analysis with anti-NMDAR1 antibodies from Cell Signaling Technology. Shown is the presence of NMDAR1 protein at ~120 kDa in equally loaded lysates from A2780, SKOV3, and A2008 ovarian cancer cell lines. (C) Confocal imaging of A2780 and SKOV3 ovarian cancer cells with PANN1 antibodies.
Figure 2 PANN1 lgG on ovarian and breast cancer cells viability.
Notes: Reductions in cell viability (± standard error of mean) of A2008, A2780, and SKOV3 human ovarian cancer cells and MCF-7 breast cancer cells compared to vehicle controls produced by incubation for 24 hours with increasing concentrations of PANN1 antibodies as an IgG preparation (n=6 at each concentration). These antibodies had no effect on HEK293 cells (not shown). Concentrations are given as fractional dilutions from original antiserum.
Figure 3 Effect ifenprodil on A2780 cells and tumors.
Notes: (A) Effects (± standard error of mean) on cell viability of A2780 ovarian cancer cells due to incubation with increasing concentrations of GluN2B antagonist ifenprodil compared with vehicle controls over 48 hours. The half-maximal inhibitory concentration was ~400 µM (n=16 at each concentration). (B) GluN2B antagonist influence on the growth of human ovarian tumor xenografts in nu/nu mice. Administration of ifenprodil at a daily dose of 2.5 mg/kg body weight for 10 days (days 0–9) significantly reduced growth of A2780 xenografts (P<0.01, n=6), while having no apparent impact on animal health.
